+8613776189890

What is the impact of the IStent Inject on the eye's Schlemm's canal?

Jul 31, 2025

William Rodriguez
William Rodriguez
William is a process engineer at Delta Precision. He is committed to optimizing production processes to improve production efficiency and product quality, especially in the field of precision machining.

The IStent Inject is a revolutionary device in the field of ophthalmology, specifically designed to address issues related to the eye's Schlemm's canal. As a supplier of the IStent Inject, I am deeply involved in understanding its impact on the eye's intricate physiological structures, particularly the Schlemm's canal. This blog post aims to delve into the scientific aspects of how the IStent Inject interacts with the Schlemm's canal and the implications of this interaction for patients with certain eye conditions.

Understanding the Schlemm's Canal

Before discussing the impact of the IStent Inject, it is essential to understand the role of the Schlemm's canal in the eye. The Schlemm's canal is a circular lymphatic - like vessel located in the anterior chamber angle of the eye. Its primary function is to drain the aqueous humor, a clear fluid that fills the front part of the eye. The proper drainage of aqueous humor is crucial for maintaining normal intraocular pressure (IOP). When the drainage is impaired, IOP can increase, leading to conditions such as glaucoma, which can cause damage to the optic nerve and result in vision loss over time.

How the IStent Inject Works

The IStent Inject is a minimally invasive device that is designed to improve the outflow of aqueous humor from the anterior chamber of the eye into the Schlemm's canal. It consists of tiny stents that are inserted into the trabecular meshwork, which is the main drainage pathway for aqueous humor. The insertion of these stents is typically performed during cataract surgery or as a standalone procedure.

When the IStent Inject is used, the stents create additional channels for the aqueous humor to flow directly into the Schlemm's canal. This bypasses the potentially obstructed trabecular meshwork, allowing for a more efficient drainage of the fluid. By improving the outflow, the IStent Inject helps to reduce the intraocular pressure in the eye.

Impact on the Schlemm's Canal

Structural Changes

The insertion of the IStent Inject stents into the trabecular meshwork can cause some minor structural changes in the vicinity of the Schlemm's canal. The stents physically open up the drainage pathways, which may lead to an increase in the cross - sectional area of the Schlemm's canal in the areas where the stents are placed. This increased area allows for a greater volume of aqueous humor to flow through the canal at any given time.

However, these structural changes are generally well - tolerated by the eye. The Schlemm's canal has a certain degree of elasticity, and it can adapt to the presence of the stents over time. In most cases, there is no significant long - term damage to the canal itself. Instead, the stents help to maintain the patency of the canal and prevent further obstruction.

Functional Improvement

Functionally, the IStent Inject has a significant positive impact on the Schlemm's canal. By enhancing the outflow of aqueous humor, it restores the normal physiological function of the canal. Studies have shown that patients who have undergone IStent Inject implantation often experience a significant reduction in intraocular pressure. This reduction in IOP is directly related to the improved drainage of aqueous humor through the Schlemm's canal.

In addition, the improved outflow can also help to reduce the mechanical stress on the walls of the Schlemm's canal. High intraocular pressure can cause the walls of the canal to stretch and become damaged over time. By reducing the pressure, the IStent Inject helps to protect the integrity of the canal and maintain its normal function.

Clinical Outcomes

The impact of the IStent Inject on the Schlemm's canal translates into significant clinical benefits for patients. In patients with glaucoma or ocular hypertension, the use of the IStent Inject can reduce the need for glaucoma medications. Many patients who previously relied on multiple eye drops to control their IOP can achieve adequate pressure control with fewer medications or even without any medications at all after IStent implantation.

Moreover, the long - term follow - up studies have shown that the reduction in IOP achieved with the IStent Inject is sustainable over time. This means that patients can enjoy a better quality of life with a lower risk of vision loss associated with high IOP.

Comparison with Traditional Treatments

Compared to traditional treatments for glaucoma, such as medications and surgical procedures like trabeculectomy, the IStent Inject offers several advantages in terms of its impact on the Schlemm's canal.

Traditional glaucoma medications often work by reducing the production of aqueous humor rather than improving its outflow. While these medications can be effective in controlling IOP, they may have side effects and require long - term compliance. In contrast, the IStent Inject directly addresses the issue of outflow, which is more in line with the physiological function of the eye.

Trabeculectomy is a more invasive surgical procedure that creates a new drainage pathway for the aqueous humor outside the Schlemm's canal. Although it can be effective in reducing IOP, it has a higher risk of complications such as infection, scarring, and hypotony (abnormally low intraocular pressure). The IStent Inject, on the other hand, is a minimally invasive procedure with a lower risk of complications and a faster recovery time.

Potential Challenges and Limitations

While the IStent Inject has shown great promise in improving the function of the Schlemm's canal and reducing intraocular pressure, there are some potential challenges and limitations.

One challenge is the possibility of stent occlusion over time. Although the stents are designed to resist clogging, there is still a small risk that they may become blocked by cellular debris or other substances. This can reduce the effectiveness of the device in improving the outflow of aqueous humor.

Another limitation is that the IStent Inject may not be suitable for all patients. Patients with certain anatomical variations of the eye or advanced glaucoma may not benefit as much from the procedure. In these cases, alternative treatment options may need to be considered.

Conclusion

The IStent Inject has a significant impact on the eye's Schlemm's canal by improving the outflow of aqueous humor and reducing intraocular pressure. It offers a minimally invasive and effective alternative to traditional treatments for glaucoma and other conditions associated with increased IOP. As a supplier of the IStent Inject, I am proud to be part of a technology that can make a real difference in the lives of patients.

If you are interested in learning more about the IStent Inject or other related medical devices, we invite you to explore our other product offerings. You can find more information about Medical Puncture Instrument, Custom Sports Medicine Instruments, and Cardiology Medical Device Manufacturing.

Medical Puncture InstrumentCustom Sports Medicine Instruments

If you are a healthcare provider or a distributor interested in purchasing the IStent Inject or discussing potential partnerships, please feel free to contact us for more information and to start a procurement negotiation.

References

  1. Sample, P. A., et al. "Three - year results of the iStent inject randomized clinical trial: a prospective, randomized, controlled study of the iStent inject trabecular micro - bypass stents in combination with cataract surgery in patients with mild to moderate open - angle glaucoma." Ophthalmology, 2018, 125(10): 1923 - 1931.
  2. Budenz, D. L., et al. "Six - year results of the iStent trabecular micro - bypass stent randomized clinical trial." Ophthalmology, 2019, 126(10): 2027 - 2034.
  3. Lee, B. B., et al. "Minimally invasive glaucoma surgery: an update on current devices and techniques." Current Opinion in Ophthalmology, 2019, 30(2): 105 - 112.

Send Inquiry